Akp-6 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of Akp-6, an isoform of the alkaline phosphatase (AP) enzyme family. Alkaline phosphatases are responsible for catalyzing the removal of phosphate groups from various molecules, a critical function in numerous biochemical pathways, including phosphate metabolism and cellular signaling. Akp-6, like other alkaline phosphatases, plays a role in dephosphorylation processes, making it essential for maintaining phosphate balance within cells. Inhibitors of Akp-6 work by binding to the enzyme's active site, preventing it from interacting with its natural substrates. These inhibitors often mimic the transition state of phosphate hydrolysis, allowing them to effectively compete with the natural phosphate-containing substrates for the active site. The molecular structure of Akp-6 inhibitors typically includes phosphate analogs or similar groups that interact with key catalytic residues, forming stable interactions that block enzyme activity.
The development of Akp-6 inhibitors involves detailed structural analysis of the enzyme, which is typically obtained through techniques such as X-ray crystallography or cryo-electron microscopy. These methods reveal the three-dimensional arrangement of the enzyme's active site, providing critical insights into how the enzyme interacts with its substrates and how inhibitors can be designed to bind more effectively. Some Akp-6 inhibitors may act allosterically, binding to sites distant from the active site and causing conformational changes that reduce the enzyme's ability to function. Computational tools such as molecular docking simulations are commonly employed to predict and refine the interactions between inhibitors and Akp-6, allowing for the optimization of binding affinity and specificity. By inhibiting Akp-6, these compounds are valuable tools for studying the role of this specific isoform in phosphate metabolism and dephosphorylation processes, providing important insights into the biochemical mechanisms that regulate phosphate homeostasis in cells.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $31.00 $83.00 | 6 | |
Theophylline, a methylxanthine drug, has been reported to inhibit alkaline phosphatases. | ||||||
L-Phenylalanine | 63-91-2 | sc-394058 sc-394058A sc-394058B | 100 g 500 g 1 kg | $112.00 $457.00 $679.00 | 1 | |
L-Phenylalanine acts as an inhibitor of various alkaline phosphatases, potentially including ALPI. | ||||||
L-Homoarginine | 156-86-5 | sc-479071 sc-479071A | 5 g 25 g | $159.00 $419.00 | ||
L-Homoarginine is an inhibitor of alkaline phosphatase activity. | ||||||
Tungstic acid | 7783-03-1 | sc-253814 | 100 g | $71.00 | ||
Tungstate is known to inhibit alkaline phosphatase enzymes. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $90.00 $251.00 | 5 | |
Zoledronate, a bisphosphonate, can inhibit alkaline phosphatases, including ALPI. | ||||||
L-(+)-Tartaric acid | 87-69-4 | sc-218622 sc-218622A sc-218622B | 100 g 500 g 2.5 kg | $52.00 $121.00 $527.00 | 1 | |
Tartrate is a competitive inhibitor of alkaline phosphatases. | ||||||
Parathyroid hormone fragment (1-34) | 52232-67-4 | sc-487943 | 100 µg | $185.00 | ||
Teriparatide, a parathyroid hormone analog, may influence alkaline phosphatase activity, including ALPI. | ||||||